絞り込み

16641

広告

「"Mitchell TC "[Author]」の検索結果

64件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma.

Noncompliance in Prospective Retina Clinical Trials: Analysis of factors predicting loss to follow up.

Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.

Human neutrophils depend on extrinsic factors produced by monocytes for their survival response to TLR4 stimulation.

Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.

Anti-CTLA4 activates intratumoral NK cells and combined with IL15/IL15R-alpha complexes enhances tumor control.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

TOX transcriptionally and epigenetically programs CD8 T cell exhaustion.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma.

Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma.

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Immunotherapy in melanoma.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

A GRIM fate for human neutrophils in airway disease.

Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

  1. 1
  2. 2
  3. 3
  4. 4
Sort by
※並べ替えは表示に時間がかかります